Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
Patent Number: 7,250,294
Date of First Priority Issue: Wednesday May 17th, 2000
Date Issued: Tuesday July 31st, 2007
Assignee: Geron Corporation (Menlo Park, CA)
Inventors: Carpenter; Melissa K. (Castro Valley, CA), Denham; Jerrod J. (San Francisco, CA), Inokuma; Margaret S. (San Jose, CA), Thies; R. Scott (Pleasanton, CA)
From Class: Differentiation
Comments: No comments
When people wonder why Geron's valuation is so high (half a billion) even though they are far from the clinic...well the answer is strong IP such as the current patent.
This patent blocks anyone from differentiating neurons from embryonic stem cells and using them to screen compounds for:
1. toxicity
2. viability in culture
3. induction of alterations in neurotransmitter synthesis, release, or uptake
4. changes electrophysiology of cells in the population.
View this patent on the USPTO website.
Added to StemCellPatents.com on Saturday August 4th, 2007
Social & Bookmarking:
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.